Liquidia (LQDA) Stock Price, News & Analysis

Company Overview

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Key Stats

• Today's Range: $9.92 to $10.25
• 50-Day Range: $8.90 to $14.11
• 52-Week Range: $5.71 to $16.99
• Volume: 1.53 million shs
• Average Volume: 1.01 million shs
• Market Capitalization: $760.32 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $23.14
• Consensus Rating: Moderate Buy

Liquidia Stock Analysis - MarketRank™

Liquidia scored higher than 74% of companies evaluated by MarketBeat, and ranked 287th out of 1,007 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Liquidia has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 5 buy ratings, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

Liquidia has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Liquidia are expected to grow in the coming year, from ($1.69) to ($1.35) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Liquidia is -6.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Liquidia is -6.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Liquidia has a P/B Ratio of 13.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

16.04% of the outstanding shares of Liquidia have been sold short.

Short Interest Ratio / Days to Cover

Liquidia has a short interest ratio ("days to cover") of 10.2, which indicates bearish sentiment.

Change versus previous month

Short interest in Liquidia has recently decreased by 1.84%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Liquidia does not currently pay a dividend.

Dividend Growth

Liquidia does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

16.04% of the outstanding shares of Liquidia have been sold short.

Short Interest Ratio / Days to Cover

Liquidia has a short interest ratio ("days to cover") of 10.2, which indicates bearish sentiment.

Change versus previous month

Short interest in Liquidia has recently decreased by 1.84%, indicating that investor sentiment is improving.

News and Social Media

• Score: 1.7 / 5
• News Sentiment: 0.04

News Sentiment

Liquidia has a news sentiment score of 0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Liquidia this week, compared to 4 articles on an average week.

Search Interest

Only 6 people have searched for LQDA on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 5.0 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Liquidia insiders have bought 455.06% more of their company's stock than they have sold. Specifically, they have bought $1,426,500.00 in company stock and sold $256,998.00 in company stock.

Percentage Held by Insiders

31.60% of the stock of Liquidia is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

64.54% of the stock of Liquidia is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

LQDA Stock Analysis - Frequently Asked Questions

How have LQDA shares performed this year?

Liquidia's stock was trading at $12.03 at the beginning of 2024. Since then, LQDA stock has decreased by 16.8% and is now trading at $10.01.
View the best growth stocks for 2024 here.

How were Liquidia's earnings last quarter?

Liquidia Co. (NASDAQ:LQDA) issued its quarterly earnings data on Wednesday, August, 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by $0.02. The company earned $3.66 million during the quarter, compared to analyst estimates of $7.92 million. Liquidia had a negative net margin of 755.46% and a negative trailing twelve-month return on equity of 183.57%.

When did Liquidia IPO?

Liquidia (LQDA) raised $50 million in an initial public offering on Thursday, July 26th 2018. The company issued 4,500,000 shares at $10.00-$12.00 per share. Jefferies and Cowen served as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.

Who are Liquidia's major shareholders?

Top institutional shareholders of Liquidia include Susquehanna International Group LLP, Bank of New York Mellon Corp (0.27%), HighVista Strategies LLC (0.16%) and Squarepoint Ops LLC (0.11%). Insiders that own company stock include Caligan Partners Lp, Russell Schundler, Michael Kaseta, Rajeev Saggar, Robert A Lippe, Scott Moomaw, Jason Adair and Arthur S Kirsch.
View institutional ownership trends.

How do I buy shares of Liquidia?

Shares of LQDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Liquidia own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Liquidia investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Aldeyra Therapeutics (ALDX), Sorrento Therapeutics (SRNE), vTv Therapeutics (VTVT), Genocea Biosciences (GNCA) and Inovio Pharmaceuticals (INO).

Company Calendar

• Last Earnings: 8/07/2024
• Today: 9/20/2024
• Next Earnings (Estimated): 11/05/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:LQDA
• CUSIP: N/A
• CIK: 1819576
• Web: www.liquidia.com
• Phone: (919) 328-4400
• Fax: N/A
• Employees: 50
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $23.14
• High Stock Price Target: $30.00
• Low Stock Price Target: $3.00
• Potential Upside/Downside: +130.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 8 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.56)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-78,500,000.00
• Net Margins: -755.46%
• Pretax Margin: -755.46%
• Return on Equity: -183.57%
• Return on Assets: -74.19%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.08
• Quick Ratio: 5.78

Sales & Book Value

• Annual Sales: $14.84 million
• Price / Sales: 51.80
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.73 per share
• Price / Book: 13.78

Miscellaneous

• Outstanding Shares: 76,414,000
• Free Float: 52,267,000
• Market Cap: $768.72 million
• Optionable: Optionable
• Beta: 0.22